Progression of thyroid tumors to advanced and less-differentiated carcinomas requires additional oncogenic alterations, including TP53 and TERT promoter mutation, and aberrant PI3K–PTEN–AKT signaling. This evidence concerns the gene AKT1 and thyroid tumor.